Listing image
A pair of hands with surgical gloves poking an injection through a small bottle.
Credit
Pongmanat Tasiri/SOPA Images/LightRocket via Getty Images
Caption

A healthcare worker prepares the Pfizer-BioNTech (Comirnaty) covid-19 vaccine during the vaccination campaign.

File size
2973349 bytes
Image width
4663px
Image height
3048px
Filename
covid-19-vaccines-the-factors-that-enabled-unprecedented-timelines-for-clinical-development-and-regulatory-authorisation.jpg
Image
A pair of hands with surgical gloves poking an injection through a small bottle.
Download allowed
On
Listing summary

This report identifies the factors that enabled the rapid clinical development and emergency use authorisation of Covid-19 vaccines.

English
Standfirst

This report identifies the factors that enabled the rapid clinical development and emergency use authorisation of Covid-19 vaccines.

Published date
Content
Admin title
Intro
Group
Body

It sets out the lessons learned to improve the vaccine ecosystem for future vaccine development, for pandemics, epidemics of emerging pathogens, and endemic diseases.

Group title
Key findings
Admin title
Key findings
Group
Body

The SARS-CoV-2 pandemic triggered concerted action by governments, funders, regulators and industry to overcome many of the historical challenges that vaccines usually face during development and authorisation.  

In 2021, Wellcome commissioned a report to identify the factors that enabled the rapid clinical development and emergency use authorisation of Covid-19 vaccines. The aim was to identify actions that would improve the development ecosystem for all vaccines.  

Key findings include: 

  • The significant health, economic and social impacts of the pandemic led to high levels of political commitment to develop vaccines against Covid-19. 
  • Unprecedented levels of investment spread the financial risks for developers and contributed to more efficient decision-making. 
  • A proactive approach by regulators giving clear indications of data requirements from the outset, coupled with prioritisation of human resources and increased collaborations resulted in accelerated review processes. 
  • The availability of existing research on coronaviruses, vaccine platform technologies, and strong clinical trial infrastructure combined with streamlined clinical testing processes resulted in faster development. 

Recommendations for actions: 

  • Commit sustained financial support for scientists and foundational science. 
  • Establish strong, flexible clinical trial infrastructure.  
  • Support and strengthen global funding mechanisms. 
  • Facilitate communication between regulatory authorities and other stakeholders by developing forums. 
Group title
Downloads
Admin title
Downloads
Group
Listing layout
Link List
Content
Linked file
JaneBracher
File size
1383898 bytes
Mime type
application/pdf
Title
Covid-19 vaccines: the factors that enabled unprecedented timelines for clinical development and regulatory authorisation
Listing text
This report identifies the factors that enabled the rapid clinical development and emergency use authorisation of Covid-19 vaccines.
Type
Group title
Contact us
Admin title
Contact us
Group
Body

For more information, contact Deborah King, Research Lead, Vaccines at D.King@wellcome.org.

Group title
Related content
Admin title
Related content
Group
Listing layout
Image card with CTA link (Horizontal card)
Content
Meta title
Covid-19 vaccines: factors that improved timelines for clinical development | Reports | Wellcome
Published on
Meta description
This report identifies the factors that enabled the rapid clinical development and emergency use authorisation of Covid-19 vaccines.
Banner styling
Banner with image above title
Exclude from listings
Off
Add noindex
Off